Skip to main content

Bioarray PGS+PGD Single Biopsy Kit

Bioarray has launched its PGS+PGD Single Biopsy kit which screens aneuploidies and identifies embryos with pathological mutation from a single biopsy sample. The kit uses next-generation sequencing technology and bioinformatics analysis to determine whether an embryo carries aneuploidies, such as trisomy of chromosome 21, and allow for users to reject embryos affected by the mutation and/or select those not affected. Users can expect results to be processed within three to five days.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.